GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma

Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas

“…17 Recently, GOLPH2 was found to be up-regulated in sera of patients with HCC compared to healthy individuals, and it was assumed that GOLPH2 might serve as a novel serum marker for HCC. 5,18 Unfortunately, the authors found the applied immunoblot assay unsuitable for routine practice. 5 Previous studies have shown a better sensitivity of GOLPH2 than AFP.…”

“…5,18 Unfortunately, the authors found the applied immunoblot assay unsuitable for routine practice. 5 Previous studies have shown a better sensitivity of GOLPH2 than AFP. 5 Serum levels of sGOLPH2 and sAFP did not correlate in our study, pointing to a diverse underlying cause of their elevation in HCC.…”

“…4 Recently GOLPH2/GP73, a Golgi apparatus-associated protein, has been shown to have a higher sensitivity than AFP in the detection of HCC. 5 Immunohistochemically, GOLPH2 has been found in normal biliary epithelial cells whereas normal hepatocytes were negative. 6 Furthermore GOLPH2 expression was significantly increased in liver disease due to viral causes (hepatitis B virus [HBV], hepatitis C virus [HCV]) compared to nonviral causes (alcohol-induced liver disease, autoimmune hepatitis).…”

Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation

“…Since the 1980s, several novel tumor markers specific for HCC have been widely investigated, and numerous studies demonstrated that the Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and Golgi protein 73 (GP73) were superior to AFP for the early diagnosis of HCC (Marrero et al, 2005;Durazo et al, 2008;Mao et al, 2010;Toyoda et al, 2011;Witjes et al, 2013), and they also could be used to monitor the response of patients to curative treatment and estimate the risk of relapse (Toyoda et al, 2008;Yamamoto et al, 2009;Mao et al, 2010;Nouso et al, 2011). However, most of these statistics were reported from Japan, and liver resection was the most commonly used curative treatment.…”

Posttranslational Protein Modifications

“…Golgi protein 73 (GP73) was a major constituent showing this particular glycan. Interest- ingly GP73 is not normally a secreted protein, thus its presence in blood (43) in combination with an atypical glycan structure, possibly reflects a pathological condition of the neoplastic cells. Moreover additional hyperfucosylated proteins in serum from liver cancer patients were identified among which the current hepatocellular carcinoma biomarker ␣-fetoprotein was found.…”